Zika Virus and Zika Virus Disease

During recent months, there has been growing international public concern about the Zika virus. As scientific understanding of the Zika virus unfolds, there are still many unanswered questions. Public health officials, clinicians, and consumers alike have questions about the Zika virus and the Zika virus disease. There is a need to know where to turn for the most up-to-date and reliable online information sources. Although aspects of Zika virus disease and associated medical conditions can be frightening, information seekers may find reassurance in the following online sources to guide their understanding of risk, prevention, transmission, affected geographical areas, symptoms, and disease management.     

Growth hormone and low dose estrogen in Turner syndrome: results of a United States multi-center trial to near-final height

A cardinal clinical feature of Turner syndrome (TS) is linear growth failure resulting in extreme short stature: the median adult height of untreated women with TS is 143 cm, 20 cm (8 in.) below that of the general female population. In the largest multicenter, randomized, long-term, dose-response study conducted in the United States, 232 subjects with TS received either 0.27 or 0.36 mg/kg.wk of recombinant human GH with either low dose ethinyl E2 or oral placebo. The study was placebo-controlled for both GH and estrogen for the first 18 months and remained placebo-controlled for estrogen for its duration. The near-final height of the 99 subjects whose bone age was at least 14 yr was 148.7 +/- 6.1 cm after 5.5 +/- 1.8 yr of GH started at a mean age of 10.9 +/- 2.3 yr; this represents an average increase of 1.3 +/- 0.6 SD scores from baseline (TS standard). Height was greater than 152.4 cm (60 in.) in 29% of subjects compared with the expected 5% of untreated patients. Mean near-final heights of subjects who received the lower GH dose, with or without estrogen, were 145.1 +/- 5.4 and 149.9 +/- 6.0 cm, respectively; those who received the higher GH dose with or without estrogen achieved mean near-final heights of 149.1 +/- 6.0 and 150.4 +/- 6.0 cm, respectively. Factors that most impacted outcome were younger age, lower bone age/chronological age ratio, lower body weight, and greater height SD score at study entry. This study demonstrates significant GH-induced improvement in height SD score, with correction of height to within the normal channels for a significant number of patients, and provides evidence of a GH dose-response effect. These data also indicate that early administration of estrogen, even at relatively low doses, does not improve gain in near-final height in patients with TS.     

Caring for the patient with mental retardation in the emergency department

There are approximately 6 million individuals with a diagnosis of mental retardation in the United States. Because of deinstitutionalization of patients with mental retardation, coupled with an increase in their life expectancy, emergency physicians are increasingly encountering and managing patients with mental retardation in the emergency department. Many emergency physicians are uncomfortable when interacting with individuals with mental retardation, which often carries over to the assessment and management of these patients in the ED. The purpose of this review is to aid the emergency physician in understanding the patient with mental retardation, their comorbid conditions, and the approach to evaluating and managing these patients in the ED.     

Cognitions and alcohol-influenced performance: the impact of reinforcement contingencies

The effects of different reinforcement conditions on self-reported cognitions and task performance under the influence of alcohol were examined. Four groups of male university students attended a series of four drinking sessions. During the sessions, the groups performed a visual tracking task under different reinforcement conditions which influence the speed of acquisition of behavioural tolerance to the impairing effects of alcohol. At the end of each session, subjects completed a questionnaire intended to elicit any thoughts, feelings, ideas or images they experienced during the session. Their responses were scored in categories related to alcohol effects, task performance and motivation. The groups differed significantly on numbers of self-reported cognitions related to general alcohol effects and to alcohol effects on task performance; these differences corresponded to differences in the speed of tolerance development. In the group that acquired tolerance most rapidly, several aspects of task performance were significantly correlated with cognitions. These data provide support for the suggestion that cognitive activity may be an important factor in individuals' responses to alcohol and other drugs.     

Validating the performance of the mammary sentinel lymph node team

BACKGROUND AND OBJECTIVES: The mammary sentinel lymph node (SLN) procedure has the potential to improve the accuracy and lower the morbidity of axillary staging in breast cancer patients, but results are closely linked to experience and can vary widely between institutions. Standardized performance measures need to be established in order to optimize the transition to SLN biopsy only. METHODS: Performance data were prospectively collected for the first 156 mammary SLN procedures performed by three surgeons in our institution. RESULTS: Seventy-five cases were required to achieve an SLN visualization rate of > 80% on preoperative lymphoscintigraphy. The SLN visualization rate was 90% for the last 52 cases. Two surgeons required 25 cases before consistently achieving a > or = 90% SLN identification rate in the operating room and one required 15 cases. The metastasis detection rate increased from 22% for the first 52 cases to 31% for the last 52 cases. The false negative rate for the procedure was 5%. CONCLUSIONS: The following performance criteria and benchmarks are suggested for validating the performance of the SLN team: (1) SLN visualization rate on preoperative lymphoscintigraphy > or = 80%, (2) SLN identification rate in the operating room > or = 90%, (3) False negative rate for the procedure 5%. Thirty procedures per surgeon were sufficient to achieve these benchmarks in our group.     

Predictors of relapse after treatment for methamphetamine use

The purpose of this study is to describe treatment utilization and relapse and examine possible predictors of time to relapse after treatment for methamphetamine (MA) use. This analysis is based on natural history interview data from 98 subjects treated for MA use in publicly-funded programs in Los Angeles County in 1995-97 and interviewed two to three years following their treatment admission. Results showed that half of the subjects had resumed MA use: 36% within six months of the end of treatment, and 15% more within seven to 19 months. Survival analysis methods showed significant predictors of (shorter) time to relapse were shorter length of treatment, older age of first substance use, and involvement in selling MA; ethnicity (being Hispanic) and more previous time in treatment had weaker effects.     

Minimizing gang violence in the emergency department.

Street gang members are frequently injured, and the violence of their subculture may follow them from the streets into the emergency department. We present four cases in which in-hospital gang violence occurred or was prevented. To decrease the risk of injury from gang-related violence within the hospital, we offer guidelines for patient care and health care provider safety. Emphasis is on education, awareness, and early hospital security involvement.     

Ethnic patterns in drug abuse treatment utilization

This study describes utilization of drug abuse treatment and related perceptions among African American, Hispanic, and Anglo drug-using arrestees in Los Angeles. The study extends prior research by, first, describing ethnic variation in treatment utilization through analyses that control for nonethnic demographic factors and by, second, exploring the degree to which ethnicity is related to two predisposing factors (attitude toward treatment and perceived need) and two enabling factors (perceived cost and availability). After nonethnic demographic factors and past drug dependence are controlled, African American and Hispanic drug users in Los Angeles are less likely to report having been in drug abuse treatment. Hispanic drug users are more likely than Anglos to say that they have not sought treatment because they do not need it. African American drug users are more likely than Anglos to hold unfavorable views of treatment. Data used in this paper were collected under National Institute of Justice (NIJ) contracts 88-IJ-CX-K005, 89-IJ-CX-R007, and 89-IJ-R-007. Data analysis and report preparation were supported by NIJ grant 90-IJ-CX-0044 and the National Institute on Drug Abuse Grant K02 DA00146.